CABA Historical PE Ratio Notes

— Cabaletta Bio (ticker symbol: CABA) is a clinical-stage biotechnology company focused on developing engineered T cell therapies for patients with autoimmune diseases. Utilizing its proprietary CABA™ platform, the company designs therapies—such as its leading candidate, DSG3-CAART—to selectively target and destroy autoimmune B cells while preserving healthy immune function. This approach is promising, but it also means Cabaletta Bio is largely pre-revenue, as its therapies are still in clinical trials and have not yet been commercialized. As a result, when reviewing historical P/E ratio data for CABA, you will likely notice periods where the company has no meaningful (or even negative) earnings, resulting in either extremely high or non-applicable P/E ratios. This is common for early-stage biotechs, where valuations are driven more by the future potential of their therapies & the progress of clinical milestones, rather than current profits. Because of this, historical P/E ratios for CABA may not be reliable indicators of company value in the way they are for established, profitable firms, and often reflect investor sentiment about the probability of successful drug development & eventual market approval rather than steady operational performance.

On this page we presented the CABA Historical PE Ratio information for Cabaletta Bio' stock. The average CABA historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 3.7. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average CABA historical PE based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this CABA historical PE result, against the recent PE: when this page was posted on 5/18/2026, the most recent closing price for CABA had been 3.29, and the most recent quarterly earnings result, annualized, was 2.08. Meanwhile, the most recent TTM earnings summed to NA. From these numbers, we calculate the recent CABA PE on 5/18/2026 based on annualized quarterly EPS was 1.6. Based on CABA's history, that recent PE is low relative to the historical average, with the recent PE 56.8% lower than the historical average PE across our data set for Cabaletta Bio.

For self directed investors doing their due diligence on CABA or any other given stock, valuation analysis for CABA can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Cabaletta Bio PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for CABA. Thanks for visiting, and the next time you need to research CABA Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.